Gastric Cancer Therapy Market to Grow with a CAGR of 6.12% through 2030
Rising Incidence of Gastric Cancer and Aging Global Population are expected to drive the Global Gastric Cancer Therapy Market in the forecast period 2026-2030
According to
TechSci Research report, “Gastric Cancer Therapy Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2030F”,
the Global Gastric Cancer Therapy Market stood at USD 3.98 Billion in 2024 and
is anticipated to grow with a CAGR of 6.12% in the forecast period, 2026-2030.
Ongoing progress in medical research and technology has significantly enhanced the development of more effective therapies for gastric cancer. In-depth studies into the molecular and genetic mechanisms underlying gastric cancer have led to the identification of new biomarkers and the creation of targeted therapies. Innovations in treatment options, such as immunotherapies, targeted therapies, and combination regimens, have proven highly effective in improving patient outcomes. As more therapies advance through clinical trials and receive regulatory approval, the gastric cancer treatment market continues to expand. The introduction of these novel therapies encourages healthcare providers to adopt them, further accelerating market growth.
Personalized or precision medicine is becoming a key trend in the treatment of gastric cancer, focusing on customizing therapies based on the unique genetic and molecular characteristics of each patient’s cancer. This approach has led to the development of therapies that are not only more effective but also less toxic than traditional treatments like chemotherapy. The shift toward personalized treatment plans is improving clinical outcomes and driving greater adoption of advanced therapies, making personalized medicine a pivotal factor in the growth of the gastric cancer therapy market.
Targeted therapies and immunotherapies have revolutionized gastric cancer treatment. Targeted therapies focus on specific molecules driving cancer cell growth, while immunotherapies enhance the body’s immune response to combat cancer cells. The success of immunotherapies, such as checkpoint inhibitors, and targeted treatments, like HER2-targeted therapies, has significantly improved survival rates, positioning these therapies as preferred treatment options. As these therapies become more widely available, they are driving substantial growth in the gastric cancer therapy market, as patients increasingly demand less invasive and more effective treatment alternatives.
Improvements in diagnostic technologies, including molecular diagnostics and advanced imaging, have enabled earlier detection of gastric cancer. Early-stage diagnoses greatly enhance the potential for successful treatment and better patient outcomes. The growing availability of screening tests and the development of minimally invasive diagnostic techniques have led to more gastric cancer cases being identified at earlier stages, which, in turn, drives demand for therapeutic interventions. Early diagnosis also increases the number of patients eligible for advanced therapies, contributing to the growth of the therapy market.
An increasing number of regulatory approvals for new gastric cancer therapies, especially targeted therapies and immunotherapies, is significantly driving market expansion. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved multiple breakthrough therapies in recent years. These approvals not only confirm the effectiveness of new treatments but also provide healthcare providers with a wider array of options for their patients. Furthermore, regulatory agencies are expediting the availability of life-saving treatments through initiatives such as accelerated approval and breakthrough therapy designations, which is further stimulating market growth. Rising patient awareness campaigns have led to a more informed public regarding the symptoms, risk factors, and available treatments for gastric cancer. Patient advocacy groups have played a crucial role in promoting early detection, raising awareness, and highlighting the benefits of advanced treatment options. As patients become more proactive in seeking medical care and making informed treatment decisions, the demand for innovative therapies increases, driving the growth of the gastric cancer therapy market.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Global
Gastric Cancer Therapy Market”
The Global
Gastric Cancer Therapy Market is segmented into therapy type, end user, regional
distribution, and company.
Based on end
user, the market is segmented into Ambulatory Surgery Centers, Hospitals and
Specialty Clinics, and Other. The Hospitals and Specialty Clinics segment was
dominated the market in 2024. This is due to their comprehensive
infrastructure, resources, and ability to handle diverse medical needs. They
provide a wide range of services under one roof, including advanced
diagnostics, surgery, and post-operative care. Additionally, hospitals offer a
multidisciplinary approach, facilitating collaboration among specialists. In
contrast, ambulatory surgery centers (ASCs) focus primarily on same-day
surgical procedures, limiting their scope. While ASCs offer convenience and
cost-effectiveness, the complexity and variety of cases treated at hospitals
and specialty clinics make them the preferred choice for patients requiring
comprehensive care, contributing to their dominance in the healthcare
landscape.
Based on region, The Asia Pacific (APAC) region is poised to experience the fastest market growth in the global gastric cancer therapy market. Asia Pacific is home to some of the highest gastric cancer incidence rates globally, with countries like Japan, South Korea, and China reporting significantly higher prevalence compared to other regions. Gastric cancer is one of the leading causes of cancer-related deaths in many APAC countries, driven by factors such as dietary habits, high rates of Helicobacter pylori infections, and genetic predispositions. This high burden of the disease results in a substantial demand for advanced therapeutic options, creating significant market potential for gastric cancer treatments in the region.
Governments and private sectors across the Asia Pacific region are increasing their investments in healthcare infrastructure, including cancer research, early detection, and treatment options. With many APAC countries prioritizing healthcare as part of their long-term development goals, there has been a notable increase in funding for cancer-related research and treatment facilities. This growth in healthcare investments is not only improving access to cancer therapies but also accelerating the adoption of advanced treatment options such as immunotherapies and targeted therapies for gastric cancer, further driving market expansion. As healthcare systems in Asia Pacific countries continue to improve, there is greater accessibility to cutting-edge cancer treatments, including newer therapies such as immunotherapies and targeted treatments. Countries like Japan, South Korea, and China have made significant strides in adopting advanced therapies due to better regulatory frameworks and more rapid approval processes for innovative treatments. As the availability of these therapies increases, both the healthcare providers and patients in the region are more inclined to adopt them, thus stimulating growth in the gastric cancer therapy market.
Major companies operating
in Global Gastric Cancer Therapy Market are:
- Abbott Laboratories Inc.
- Amgen, Inc.
- Celltrion Inc.
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Agilent Technologies Inc.
- AstraZeneca Plc
- Pfizer Inc.
- Eli Lilly & Co.
- GlaxoSmithKline Plc
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“The increasing
incidence of gastric cancer worldwide, necessitating effective treatment
solutions. Advances in therapeutic approaches, particularly the emergence of
immunotherapies and precision medicine, are revolutionizing treatment paradigms
and improving patient outcomes. Additionally, Collaborative research and
development efforts among pharmaceutical companies, research institutions, and
healthcare organizations are yielding innovative therapies and treatment
regimens. The aging global population is intensifying the demand for
personalized therapies, as the elderly are at higher risk of developing gastric
cancer. Government support, favorable regulatory environments, and a growing
focus on healthcare infrastructure development are contributes to foster the
demand for Global Gastric Cancer Therapy Market in the forecast period” said
Mr. Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Gastric Cancer Therapy Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery), By End User (Ambulatory Surgery Centers, Hospitals and Specialty Clinics, Other), By Region & Competition, 2020-2030F”, has
evaluated the future growth potential of Global Gastric Cancer Therapy Market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Gastric Cancer Therapy Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com